Trials / Completed
CompletedNCT00382213
A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 210 (planned)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy of treatment with olmesartan medoxomil, an Angiotensin Receptor Blocker, compared to placebo on the blood levels of surrogate markers of vascular inflammation for atherosclerotic disease. Patients will be randomized to receive either olmesartan medoxomil or placebo for one year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olmesartan medoxomil | |
| DRUG | Placebo |
Timeline
- Start date
- 2000-06-01
- Completion
- 2004-12-01
- First posted
- 2006-09-28
- Last updated
- 2023-06-01
Source: ClinicalTrials.gov record NCT00382213. Inclusion in this directory is not an endorsement.